NCT04477876View on ClinicalTrials.gov

Study of CD160, an Activating NK Cell Receptor, in Melanoma: a Potential Therapeutic Target?

Not yet recruitingOBSERVATIONAL

Enrollment

55

Participants

Timeline

Start Date

September 1, 2020

Primary Completion Date

December 15, 2027

Study Completion Date

December 15, 2027

Conditions

Melanoma

All Listed Sponsors

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT04477876 - Study of CD160, an Activating NK Cell Receptor, in Melanoma: a Potential Therapeutic Target? | Biotech Hunter | Biotech Hunter